AsianScientist (Dec. 9, 2013) – Shanghai Institute of Materia Medica (SIMM) and Crown BioScience, Inc. have agreed to jointly build a mouse clinical trial (MCT) center in China.
The mouse clinical center will feature advanced translational oncology platforms with fully annotated collections of patient derived xenograft (PDX) models. The immediate focus of the Center will be to combine the existing model collections of both organizations and build several thousand more new models focusing on major Asian cancer types, including liver, lung, gastric and colorectal cancers.
It will also help to accelerate the development of SIMM’s pipeline of novel and rich targeted oncology drug candidates, by leveraging Crown’s advanced oncology discovery and translational capabilities, such as its proprietary HuPrime®1.0, 2.0, 3.0, HuKemia®, HuTrialTM, HuSignatureTM platforms.
“The premium oncology translational research platform based on PDX models will enable us to have a better understanding of our candidate drugs and to stratify the responsive subgroup patients for personalized therapy,” said Dr. Jian Ding, director general of SIMM.
“Crown is very happy to partner with SIMM, the premium drug discovery CAS institute in China, to offer the world with first class translational oncology services, and ultimately benefit cancer patients all around the world,” said Dr. Jean-Pierre Wery, president of Crown BioScience.
——
Source: Shanghai Institute of Materia Medica.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
